The Directorate of Food and Drugs Administration, Goa (DFDA), on January 13, 2026, issued an advisory informing that the Central Government has prohibited the manufacture, sale, and distribution of all oral formulations containing Nimesulide above 100 mg in immediate-release dosage form, following the recommendation of the Drugs Technical Advisory Board, citing potential risk to human health and availability of safer alternatives.
The advisory directs all drug retailers, wholesalers, manufacturers, government and private hospitals, dispensaries, medical institutions, and registered medical practitioners across the State of Goa to comply with the ban strictly. Medical practitioners have been advised not to prescribe such formulations, while retailers and wholesalers must ensure that these drugs are neither dispensed nor distributed in any form.
All concerned establishments are required to identify the banned formulations in their premises, remove them from stock, and return them to suppliers with due intimation to the Directorate. Any violation or non-compliance shall invite stringent penal action under the Drugs and Cosmetics Act.
[Notification No. DI/INF/AXP/SS/SN/206/1134]
